MK-1084, CAS 2641216-67-1

Product Description: MK-1084 is a selective KRAS G12C inhibitor that is currently in Phase I clinical trial (NCT05067283). MK-1084 exhibits anticancer activity and can be used either alone or in combination with pembrolizumab (HY-P9902) for cancer research[1].

Applications: Cancer-Kinase/protease

Formula: C32H31ClF2N6O4

References: [1]Rojas C, et al. 663P Safety and preliminary efficacy of the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC[J]. Annals of Oncology, 2023, 34: S466-S467./[2]Ma X, et al., Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor. J Med Chem. 2024 Jul 11;67(13):11024-11052.

CAS Number: 2641216-67-1

Molecular Weight: 637.08

Compound Purity: 99.82

Research Area: Cancer

Solubility: DMSO : 100 mg/mL (ultrasonic)

Target: Ras

• Artikelnummer: MEXHY-162431-50
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-162431-50
• Verpackungseinheit: 50 mg
• Mengeneinheit: STK